# A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

> **NCT07232589** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 24 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nemtabrutinib
- **DRUG:** Diltiazem

## Key facts

- **NCT ID:** NCT07232589
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-12-08
- **Primary completion:** 2026-05-04
- **Final completion:** 2026-05-16
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232589

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232589, "A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07232589. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*